American Journal of Hematology

Papers
(The TQCC of American Journal of Hematology is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Hematological findings and complications of COVID‐191221
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination314
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management235
Thrombosis in COVID‐19222
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management210
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management187
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures158
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management144
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies138
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine127
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management118
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis115
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA112
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy106
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management104
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study93
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center90
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine89
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients83
Rapid and severe Covid‐19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab81
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring76
Critically ill COVID‐19 infected patients exhibit increased clot waveform analysis parameters consistent with hypercoagulability76
Acute myeloid leukemia: 2021 update on risk‐stratification and management73
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management72
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management70
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY69
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab68
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management68
Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and management67
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism67
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management63
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma63
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation63
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality60
Recommendations for diagnosis and treatment of methemoglobinemia56
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment53
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell 53
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 152
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients51
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life50
Increased blood viscosity and red blood cell aggregation in patients with COVID‐1950
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction50
Dramatic improvement after tocilizumab of severe COVID‐19 in a child with sickle cell disease and acute chest syndrome50
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments49
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management49
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma47
SARS‐CoV‐2 infection in beta thalassemia: Preliminary data from the Italian experience47
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine46
The first case of acquired hemophilia A associated with SARS‐CoV‐2 infection46
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema45
The use of venetoclax‐based salvage therapy for post‐hematopoietic cell transplantation relapse of acute myeloid leukemia44
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases44
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study44
Hematologic parameters in patients with COVID‐19 infection: a reply43
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment42
Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow?42
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report41
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients41
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event40
Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease40
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of Eu39
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients39
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management38
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors38
High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicen37
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study37
2021 clinical trials update: Innovations in hemophilia therapy37
2021 update on clinical trials in β‐thalassemia37
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist37
Heparin induced thrombocytopenia antibodies in Covid‐1937
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies36
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study35
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial34
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study32
Real‐Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT‐HU cohort study31
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping31
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach30
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib30
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms30
Prognostic factors and long‐term follow‐up of basiliximab for steroid‐refractory acute graft‐versus‐host disease: Updated experience from a large‐scale study30
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis29
Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 u29
Cell‐type‐specific insights into iron regulatory processes29
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia29
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data28
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia28
Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia28
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis28
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes27
Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later27
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management27
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease27
Follicular lymphoma: 2023 update on diagnosis and management27
Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study27
Large granular lymphocytic leukemia – A retrospective study of 319 cases26
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival26
Patient‐reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium25
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis25
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy25
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond25
The emergence of methemoglobinemia amidst the COVID‐19 pandemic25
Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry25
Familial thrombocytopenia flare‐up following the first dose of mRNA‐1273 Covid‐19 vaccine25
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies25
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma25
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression24
Myeloid and lymphoid vacuolation in VEXAS syndrome24
Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success24
Circulating endothelial cells in COVID‐1924
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment24
Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria24
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact24
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia24
Optical genome mapping for structural variation analysis in hematologic malignancies23
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients23
Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi‐c23
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma23
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update23
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia23
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure af23
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option23
Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management22
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results22
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management22
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis22
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL‐1308 trial22
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations22
Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study22
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients22
Ecarin based coagulation testing22
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis22
Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia22
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi22
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study21
Methotrexate and cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis: A single arm, single center, prospective phase 2 study21
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations21
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients21
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors21
Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease21
Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias21
An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology21
Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study21
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study21
Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination21
Role of imaging in multiple myeloma20
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost20
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event20
SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center20
The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States20
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID‐19)20
Care of patients with hemoglobin disorders during the COVID‐19 pandemic: An overview of recommendations20
Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia20
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia20
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management20
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials20
Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment20
Glucose‐6‐phosphate dehydrogenase deficiency‐associated hemolysis and methemoglobinemia in a COVID‐19 patient treated with chloroquine20
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients20
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management20
Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France20
Viscoelastic hemostatic assays: Update on technology and clinical applications20
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy20
Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism19
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results19
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes19
Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution19
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses19
Iron and platelets: A subtle, under‐recognized relationship19
Risk of invasive fungal infections in patients with high‐risk MDS and AML receiving hypomethylating agents19
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice19
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes19
Current approaches to management of high‐risk multiple myeloma19
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management19
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial18
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c18
Decitabine and venetoclax for IDH1/2mutated acute myeloid leukemia18
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival18
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia18
Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study18
Current approaches to management of newly diagnosed multiple myeloma18
Immune thrombocytopenia due to COVID‐19 during pregnancy18
CD34+ cell dose effects on clinical outcomes after T‐cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem ce18
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study18
Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH18
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease18
Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy18
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease17
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib17
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia17
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)17
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis17
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease17
Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease17
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study17
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management17
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry17
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts17
Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B‐cell lymphocytosis beyond the CLL international prognostic index17
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia17
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm17
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma17
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions17
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins17
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study16
From Hematologistʼs desk: The effect of COVID‐19 on the blood system16
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia16
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years16
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia16
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis16
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management16
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies16
Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study16
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance16
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia16
Management of CLL patients early in the COVID‐19 pandemic: An international survey of CLL experts16
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial16
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist16
Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation16
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia15
Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management15
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen15
Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy15
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases15
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma15
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia15
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs15
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the15
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia15
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy15
Genetic screening of children with marrow failure. The role of primary Immunodeficiencies14
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukem14
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management14
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor14
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival14
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study14
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management14
Diagnostic work‐up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium14
Parenteral iron therapy and phosphorus homeostasis: A review14
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study14
Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study14
Plasma P‐selectin is an early marker of thromboembolism in COVID‐1914
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course14
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL114
Functional role of endothelial transferrin receptor 1 in iron sensing and homeostasis14
Laboratory misdiagnosis of von Willebrand disease in post‐menarchal females: A multi‐center study14
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success14
Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts14
Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting14
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio14
Survival analysis in treated plasmablastic lymphoma patients: a population‐based study13
0.040565967559814